Literature DB >> 33716938

Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers.

Eileen E Moran1,2, Susan B Bressman3,4, Roberto A Ortega3,4, Deborah Raymond3,4, William C Nichols5, Christina A Palmese3,4, Sonya Elango3,4, Matthew Swan3,4, Vicki Shanker3,4, Imali Perera3, Cuiling Wang6, Molly E Zimmerman1, Rachel Saunders-Pullman3,4.   

Abstract

Mutations and variants in the glucocerebrosidase (GBA) gene are among the most common genetic risk factors for the development of Parkinson's disease (PD). Yet, penetrance is markedly reduced, and less is known about the burden of carrying a single mutation among those without diagnosed PD. Motor, cognitive, psychiatric, and olfactory functioning were assessed in 30 heterozygous GBA mutation carriers without PD (the majority of whom had mild GBA mutations) and 49 non-carriers without PD. Study focus was on domains affected in GBA mutation carriers with PD, as well as those previously shown to be abnormal in GBA mutation carriers without PD. GBA mutation carriers showed poorer performance on the Stroop interference measure of executive functioning when controlling for age. There were no group differences in verbal memory, Montreal Cognitive Assessment (MoCA), overall motor score, or presence of REM sleep behavior disorder or depression. Although total olfaction scores did not differ, GBA mutation carriers with hyposmia had lower global cognition scores than those without hyposmia. As anticipated by the low penetrance of GBA mutations, these findings suggest that pre-manifest non-motor or motor features of PD may not present in most GBA mutation carriers. However, there is support that there may be a subtle difference in executive functioning among some non-manifesting heterozygous GBA mutation carriers, and, combined with olfaction, this may warrant additional scrutiny as a potential biomarker for pre-manifest and pre-clinical GBA related PD.
Copyright © 2021 Moran, Bressman, Ortega, Raymond, Nichols, Palmese, Elango, Swan, Shanker, Perera, Wang, Zimmerman and Saunders-Pullman.

Entities:  

Keywords:  GBA; Parkinson's disease; cognition; executive functioning; glucocerebrosidase

Year:  2021        PMID: 33716938      PMCID: PMC7952874          DOI: 10.3389/fneur.2021.635958

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  30 in total

1.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

2.  Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.

Authors:  David Crosiers; Aline Verstraeten; Eline Wauters; Sebastiaan Engelborghs; Karin Peeters; Maria Mattheijssens; Peter P De Deyn; Jessie Theuns; Christine Van Broeckhoven; Patrick Cras
Journal:  Neurosci Lett       Date:  2016-07-07       Impact factor: 3.046

Review 3.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

4.  Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Authors:  R N Alcalay; E Caccappolo; H Mejia-Santana; M -X Tang; L Rosado; M Orbe Reilly; D Ruiz; B Ross; M Verbitsky; S Kisselev; E Louis; C Comella; A Colcher; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; M Rezak; K Novak; J H Friedman; R Pfeiffer; L Marsh; B Hiner; A Siderowf; H Payami; E Molho; S Factor; R Ottman; L N Clark; K Marder
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

5.  Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.

Authors:  Rachel Saunders-Pullman; Johann Hagenah; Vijay Dhawan; Kaili Stanley; Gregory Pastores; Swati Sathe; Michele Tagliati; Kelly Condefer; Christina Palmese; Norbert Brüggemann; Christine Klein; Am Roe; Ruth Kornreich; Laurie Ozelius; Susan Bressman
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

6.  A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.

Authors:  Noa Bregman; Avner Thaler; Anat Mirelman; Rick C Helmich; Tanya Gurevich; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Bastiaan R Bloem; Nir Giladi
Journal:  Brain Struct Funct       Date:  2016-07-11       Impact factor: 3.270

7.  Association of glucocerebrosidase mutations with dementia with lewy bodies.

Authors:  Lorraine N Clark; Lykourgos A Kartsaklis; Rebecca Wolf Gilbert; Beatriz Dorado; Barbara M Ross; Sergey Kisselev; Miguel Verbitsky; Helen Mejia-Santana; Lucien J Cote; Howard Andrews; Jean-Paul Vonsattel; Stanley Fahn; Richard Mayeux; Lawrence S Honig; Karen Marder
Journal:  Arch Neurol       Date:  2009-05

8.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Authors:  Ganqiang Liu; Brendon Boot; Joseph J Locascio; Iris E Jansen; Sophie Winder-Rhodes; Shirley Eberly; Alexis Elbaz; Alexis Brice; Bernard Ravina; Jacobus J van Hilten; Florence Cormier-Dequaire; Jean-Christophe Corvol; Roger A Barker; Peter Heutink; Johan Marinus; Caroline H Williams-Gray; Clemens R Scherzer
Journal:  Ann Neurol       Date:  2016-11       Impact factor: 10.422

9.  Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study.

Authors:  Roberta Balestrino; Sara Tunesi; Silvana Tesei; Leonardo Lopiano; Anna L Zecchinelli; Stefano Goldwurm
Journal:  Mov Disord       Date:  2020-08-07       Impact factor: 10.338

10.  Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.

Authors:  Michelle Beavan; Alisdair McNeill; Christos Proukakis; Derralynn A Hughes; Atul Mehta; Anthony H V Schapira
Journal:  JAMA Neurol       Date:  2015-02       Impact factor: 18.302

View more
  3 in total

1.  Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.

Authors:  Gian Pal; Graziella Mangone; Emily J Hill; Bichun Ouyang; Yuanqing Liu; Vanessa Lythe; Debra Ehrlich; Rachel Saunders-Pullman; Vicki Shanker; Susan Bressman; Roy N Alcalay; Priscilla Garcia; Karen S Marder; Jan Aasly; M Maral Mouradian; Samantha Link; Marc Rosenbaum; Sharlet Anderson; Bryan Bernard; Robert Wilson; Glenn Stebbins; William C Nichols; Marie-Laure Welter; Sepehr Sani; Mitra Afshari; Leo Verhagen; Rob M A de Bie; Tom Foltynie; Deborah Hall; Jean-Christophe Corvol; Christopher G Goetz
Journal:  Ann Neurol       Date:  2022-01-25       Impact factor: 11.274

Review 2.  Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Jingxuan Huang; Yangfan Cheng; Chunyu Li; Huifang Shang
Journal:  Transl Neurodegener       Date:  2022-04-08       Impact factor: 8.014

Review 3.  Glucocerebrosidase mutations and Parkinson disease.

Authors:  Sophia R L Vieira; Anthony H V Schapira
Journal:  J Neural Transm (Vienna)       Date:  2022-08-06       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.